The abstract is read at the publisher; the summary is JClub's.
In an adult C57BL/6J mouse model of pemphigus vulgaris, MEK1/2 inhibition with selumetinib attenuated clinical lesion severity and reduced MEK1/2 phosphorylation in lesional mucosa.
- Why it matters: PV therapies suppress autoantibodies but do not directly restore desmosomal adhesion, leaving a gap for treatments that stabilize keratinocyte cohesion.
- What they did: Adult mice received repeated intravenous injections of AK47ch, a recombinant monospecific anti-Dsg3 IgG1, to induce PV-like oral lesions within 12 days; affected mice were then treated with selumetinib, and buccal mucosa biopsies were profiled by targeted NanoString nCounter.
- The result: MEK1/2 inhibition was linked to lower inflammatory, chemokine, cytokine, and interferon-associated transcript expression and higher cellular homeostasis transcripts, enabling preclinical testing of desmosome-stabilizing therapies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.